Evolus (NASDAQ: EOLS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.330 | -0.310 | 0.0200 | ||||
REV | 30.570M | 33.908M | 3.338M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Evolus (NASDAQ: EOLS) through any online brokerage.
Other companies in Evolus’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Theravance Biopharma (NASDAQ:TBPH), GH Research (NASDAQ:GHRS), CinCor Pharma (NASDAQ:CINC) and Sundial Growers (NASDAQ:SNDL).
The latest price target for Evolus (NASDAQ: EOLS) was reported by Needham on Thursday, June 23, 2022. The analyst firm set a price target for 18.00 expecting EOLS to rise to within 12 months (a possible 40.85% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Evolus (NASDAQ: EOLS) is $12.78 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Evolus.
Evolus’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Evolus.
Evolus is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.